Name
CBI
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for CBI
Name
Alternate Names
Avastin
rhuMAB-VEGF
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--antiangiogenesis agent
Recombinant human anti-VEGF.
Vascular endothelial growth factor receptor inhibitor
NSC Number
704865
Primary Site
Breast- see remarks
Fallopian tube
Ovary
Peritoneum
colorectal
kidney
lung
multiple myeloma
Brain
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Avastin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheliĀ¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgiĀ¬cal resection
June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.
December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy
FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheliĀ¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgiĀ¬cal resection
June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.
December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy
Coding
This drug should be coded
Name
Alternate Names
C 225
C-225
C225
Erbitux
IMC-C225
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
NSC Number
714692
Primary Site
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, cetuximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code cetuximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas
Anti-VEGFr chimeric monoclonal antibody.
FDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas
Anti-VEGFr chimeric monoclonal antibody.
Coding
This drug should be coded
Name
Alternate Names
Camptosar
Camptosar Oral
Camptothecin-11
CPT 11
CPT-11
CPT11
U-101440E
Abbreviations
None
Category
Chemotherapy
Subcategory
Topoisomerase inhibitor
NSC Number
616348
Primary Site
Colorectal
head & neck
Non-small cell lung cancer (NSCLC)
pancreatic cancer
Small cell lung cancer (SCLC)
Histology
None
Remarks
Phase I (head & neck) Phase III SCLC pancreatic Topoisomerase I inhibitor. FDA approved use on colorectal cancer. Pharmacia.
Coding
This drug should be coded